Search

T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy

This press release is originally found here: http://prn. to/2YF7Js3

THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).

Read more

Highlights from the SWG

Participation in EHA and ASH congresses. Planning of new common trials. Conduct of annual EMSCO meeting in Nice in October 2023.

Read more